☆ 4.4 Article

Retrospective comparative study of the efficacy of JAK inhibitor (tofacitinib) in the treatment of systemic sclerosis-associated interstitial lung disease

CLINICAL RHEUMATOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Radiology, Nuclear Medicine & Medical Imaging

Chest high-resolution computed tomography in patients with connective tissue disease: pulmonary conditions beyond the usual suspects

Lorenzo Cereser et al.

Summary: Connective tissue diseases (CTDs) are a group of autoimmune disorders, including various types of diseases. High-resolution computed tomography (HRCT) of the chest is the preferred imaging method for evaluating interstitial lung disease (CTDs-ILD) associated with CTDs. This paper aims to provide an up-to-date review of unusual pulmonary CTD-related conditions that radiologists should be aware of.

CURRENT PROBLEMS IN DIAGNOSTIC RADIOLOGY (2022)

Add to Collection

Article Rheumatology

C-reactive protein and ground-glass opacity as predictors for intractable interstitial lung disease in patients with systemic sclerosis under cyclophosphamide treatment regardless of concomitant glucocorticoids

Yusuke Yoshida et al.

Summary: High CRP levels and non-widespread GGO predicted progressive ILD in SSc patients treated with CYC, regardless of the combined use of GCs. Temporary response to CYC was seen in SSc-ILD with high inflammation, but therapeutic effects deteriorated soon after stopping CYC.

MODERN RHEUMATOLOGY (2022)

Add to Collection

Review Biology

Potential Role of JAK Inhibitors in the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease: A Narrative Review from Pathogenesis to Real-Life Data

Elisa Fiorentini et al.

Summary: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is a serious and fatal complication with limited treatment options. Janus kinase inhibitors (JAKinibs), with their anti-inflammatory and anti-fibrotic properties, may serve as an interesting therapeutic option for SSc-ILD.

LIFE-BASEL (2022)

Add to Collection

Review Rheumatology

Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)

Paolo Spagnolo et al.

Summary: This study discusses the different types of interstitial lung diseases (ILDs) and their association with autoimmune and connective tissue diseases (CTDs), as well as introduces drug treatment studies for some fibrosing ILDs. It emphasizes the importance of fibrosis in ILDs.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Pathology

Interstitial lung disease associated with connective tissue disease

Annette Fisseler-Eckhoff et al.

Summary: Interstitial lung disease (ILD) is the most common organ manifestation in rheumatic autoimmune diseases, causing varying degrees of damage to the small airways, interstitial tissue, and blood vessels depending on the underlying autoimmune disease. A precise diagnosis and multidisciplinary approach are crucial for the management of ILD.

PATHOLOGE (2021)

Add to Collection

Review Rheumatology

Treatment for systemic sclerosis-associated interstitial lung disease

David Roofeh et al.

Summary: The review provides an overview of current treatments for systemic sclerosis-interstitial lung disease (SSc-ILD) and proposes a conceptual framework for disease management. Treatment options include traditional cytotoxic therapies, biologic disease-modifying rheumatic drugs, antifibrotic agents, autologous hematopoietic stem cell transplant, and lung transplantation. The optimal use of each option varies depending on SSc-ILD severity, progression, and comorbidities.

CURRENT OPINION IN RHEUMATOLOGY (2021)

Add to Collection

Article Rheumatology

Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound

Rositsa Valerieva Karalilova et al.

Summary: SSc patients have a markedly activated JAK/STAT signaling pathway. TOF is more effective than MTX in reducing skin and musculoskeletal involvement in SSc, with satisfactory safety.

RHEUMATOLOGY INTERNATIONAL (2021)

Add to Collection

Review Rheumatology

An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years

Corrado Campochiaro et al.

Summary: New molecular mechanisms for treating systemic sclerosis (SSc) patients have emerged, with specific drugs showing potential in various clinical trials, and some have already been approved. These studies offer hope for SSc patients, with the future challenge lying in developing personalized precision medicine for SSc treatment.

ARTHRITIS RESEARCH & THERAPY (2021)

Add to Collection

Article Rheumatology

Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis

Hanxiao You et al.

Summary: The study analyzed the effectiveness of tofacitinib in treating refractory skin thickening in dcSSc patients, showing improvements in skin score in a short period and a better performance compared to the control group. Tofacitinib-treated patients had a significantly shorter response time and higher response rates than the comparators.

RHEUMATOLOGY (2021)

Add to Collection

Article Allergy

JAK Inhibitors: Prospects in Connective Tissue Diseases

Hanxiao You et al.

CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2020)

Add to Collection

Article Pharmacology & Pharmacy

Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease

Alain Lescoat et al.

BIOCHEMICAL PHARMACOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Jonathan H. Chung et al.

JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2020)

Add to Collection

Article Rheumatology

The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib

Wenxia Wang et al.

JOURNAL OF SCLERODERMA AND RELATED DISORDERS (2020)

Add to Collection

Article Rheumatology

Pathogenesis of systemic sclerosis associated interstitial lung disease

Svetlana Nihtyanova et al.

JOURNAL OF SCLERODERMA AND RELATED DISORDERS (2020)

Add to Collection

Review Oncology

Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases

Anniina T. Virtanen et al.

BIODRUGS (2019)

Add to Collection

Article Rheumatology

Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study

Kazuki M. Matsuda et al.

ARTHRITIS RESEARCH & THERAPY (2019)

Add to Collection

Article Rheumatology

Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study

Ariane L. Herrick et al.

ANNALS OF THE RHEUMATIC DISEASES (2018)

Add to Collection

Letter Dermatology

The use of JAK inhibitors in the treatment of progressive systemic sclerosis

S. C. Deverapalli et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)

Add to Collection

Article Rheumatology

A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sjogren's syndrome-related interstitial lung disease in a Chinese population

Xin Dong et al.

CLINICAL RHEUMATOLOGY (2018)

Add to Collection

Article Rheumatology

Clinical Characteristics of Systemic Sclerosis With Interstitial Lung Disease

Eunju Jung et al.

ARCHIVES OF RHEUMATOLOGY (2018)

Add to Collection

Review Pharmacology & Pharmacy

JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects

Shubhasree Banerjee et al.

DRUGS (2017)

Add to Collection

Article Rheumatology

2013 Classification Criteria for Systemic Sclerosis An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative

Frank van den Hoogen et al.

ARTHRITIS AND RHEUMATISM (2013)

Add to Collection

Review Radiology, Nuclear Medicine & Medical Imaging

Fleischner Society: Glossary of terms tor thoracic imaging

David M. Hansell et al.

RADIOLOGY (2008)

Add to Collection

Review Rheumatology

Incidence and prevalence of systemic sclerosis: A systematic literature review

Helene Chifflot et al.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2008)

Add to Collection

Article Rheumatology

Changes in causes of death in systemic sclerosis, 1972-2002

Virginia D. Steen et al.

ANNALS OF THE RHEUMATIC DISEASES (2007)

Add to Collection

Article Rheumatology

Predictors of end stage lung disease in a cohort of patients with scleroderma

C Morgan et al.

ANNALS OF THE RHEUMATIC DISEASES (2003)

Add to Collection

Article Rheumatology

Mortality and prognostic factors in Spanish patients with systemic sclerosis

CP Simeon et al.

RHEUMATOLOGY (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.